ResMedASX:RMD +3.29%98 EV-to-FCF is 14.85 as of Jun. 24, 2026, which is 61% below its 10-year median of 37.86. GuruFocus rates ASX:RMD with a GF Score™ of 98/100 and a GF Value™ of A$38.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 418 Medical Devices & Instruments companies, ResMed ranks better than 68.66% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ResMed's Enterprise Value is A$38,499 Mil.
ResMed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was A$2,592 Mil. Therefore, ResMed's EV-to-FCF for today is 14.85.
The historical rank and industry rank for ResMed's EV-to-FCF or its related term are showing as below:
ASX:RMD'
s EV-to-FCF Range Over the Past 10 Years
Min: 15.36 Med: 37.86 Max: 185.56
Current: 15.51
During the past 13 years, the highest EV-to-FCF of ResMed was 185.56. The lowest was 15.36. And the median was 37.86.
ASX:RMD's EV-to-FCF is ranked better than 68.66% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.66
vs ASX:RMD: 15.51
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-24), ResMed's stock price is A$27.93.
ResMed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$1.548. Therefore, ResMed's PE Ratio (TTM) for today is 18.04.
ResMed (ASX:RMD) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ResMed's share price for today is A$27.93.
ResMed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$1.548.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ResMed EV-to-FCF Related Terms
ResMed EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ResMed's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ResMed's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ResMed's EV-to-FCF falls into.
ResMed's current Enterprise Value is A$38,499 Mil.
ResMed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$2,592 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (ASX:RMD) has a EV-to-FCF of 14.85 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ResMed and its competitors. This is 61% below median its historical median of 37.86. Over the past decade, ResMed's EV-to-FCF has ranged from 15.36 to 185.56. According to the industry distribution chart, ResMed ranks #131 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 31.3%.
Is ResMed's EV-to-FCF too high?
ResMed's current EV-to-FCF of 14.85 is 61% below median its 10-year median of 37.86. Over the past 10 years, this metric has ranged from a low of 15.36 to a high of 185.56. The Medical Devices & Instruments industry median EV-to-FCF is 22.66. ResMed's value of 14.85 is 34.5% below this industry median. Based on the distribution chart, ResMed ranks #131 out of 418 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ResMed has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's EV-to-FCF compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #131 out of 418 companies for EV-to-FCF. This puts ResMed in the upper half of its industry. The industry median EV-to-FCF is 22.66. ResMed's value of 14.85 is 34.5% below this benchmark. Historically, ResMed's own EV-to-FCF has ranged from 15.36 to 185.56 over the past decade. While the company's 10-year median is 37.86 vs. the industry median of 22.66, ResMed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.66, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current EV-to-FCF of 14.85 is 34.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current EV-to-FCF is 14.85, which is 61% below median its own 10-year median of 37.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$38.56, compared to a current price of A$27.93 — trading 27.6% below its estimated fair value. The current EV-to-FCF is 14.85, which is 61% below median its 10-year median of 37.86 and 34.5% below the Medical Devices & Instruments industry median of 22.66. ResMed's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ResMed (ASX:RMD), the current EV-to-FCF is 14.85 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (ASX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of A$27.93 is trading 27.6% below its estimated GF Value™ of A$38.56.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for ASX:RMD:
EV-to-FCF: 14.85 (61% below median its 10-year median of 37.86)
GF Value™: A$38.56 vs. price of A$27.93 (27.6% below fair value)
Industry Position: 34.5% below the Medical Devices & Instruments median (#131 of 418)
No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
98GF Score
Get the complete analysis for ASX:RMD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RMD has been successfully added to your 
